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However, recent randomized controlled trials (RCTs) have 
demonstrated that Hb correction to normal levels increases 
the risk of major cardiovascular (CV) events (1-5). Although the 
reasons are still unclear, the cumulative ESA dose and rapid Hb 
fluctuations may at least partly explain these findings (6-10). 
Hence, limiting ESA to the minimal dose needed to achieve the 
suggested Hb targets in end-stage renal disease (ESRD) as well 
as identifying factors associated with ESA response seems ad-
visable (6-10).
Among other factors, mineral metabolism abnormalities 
(chronic kidney disease–mineral bone disorder [CKD-MBD]) 
have repeatedly been associated with poor outcomes and have 
emerged as a risk factor for severe anemia as well as for use of 
large ESA doses (11-13). In this regard, a few observational stud-
ies have suggested a linear inverse association between para-
thyroid hormone (PTH) and ESA dose in ESRD patients (11, 12), 
although these findings may be the result of a faster deteriora-
tion of the CV system associated with higher PTH levels (14).
Due to the lack of RCTs that clearly demonstrate any sur-
vival benefit associated with strict PTH control, the latest 
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Introduction
Anemia is one of the most worrisome complications of 
chronic kidney disease (CKD). Numerous prospective studies 
have repeatedly documented an increased risk of morbidity 
and mortality associated with lower levels of hemoglobin 
(Hb) (1-5). Hence the international guidelines on patient care 
suggest the use of erythropoietin-stimulating agents (ESAs), 
iron and folate supplementation for anemia correction in CKD 
individuals (1-5).
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Background: Whether anemia and mineral bone abnormalities (chronic kidney disease–mineral bone disorder 
[CKD-MBD]) are associated still remains to be elucidated. Both anemia and CKD-MBD have been associated with 
adverse cardiovascular outcome and poor quality of life. However, recent evidence suggests that use of large 
doses of erythropoietin-stimulating agents (ESAs) to correct hemoglobin (Hb) may be detrimental in CKD. The Op-
timal Anemia Treatment in End Stage Renal Disease (ESRD) (Optimal ESRD Treatment) study will assess whether 
lowering of parathyroid hormone (PTH) is associated with a reduction in ESA consumption.
Methods: The Optimal ESRD Treatment study is a pilot single-center open-label study with blinded end point (a 
prospective randomized open blinded end-point [PROBE] design) enrolling 50 patients on maintenance dialysis. 
Eligible patients with intact PTH (iPTH) 300-540 pg/mL and Hb 10-11.5 g/dL will be randomized 1:1 to strict PTH 
control (150-300 pg/mL) versus standard care (PTH range 300-540 pg/mL). Available drugs for CKD-MBD and 
anemia treatment will be managed by the attending physician to maintain the desired levels of PTH (according to 
study arm allocation) and Hb (10-11.5 g/dL). Echocardiographic data for cardiac structure and function as well as 
arterial stiffness will be assessed at study inception and completion.
Conclusions: The Optimal ESRD Treatment study should shed light on the complicated interplay of anemia and 
CKD-MBD and on the feasibility of clinical trials in this domain. The study results are expected in the spring of 
2017.
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Kidney Disease: Improving Global Outcomes (KDIGO) guide-
lines on CKD-MBD management suggest a higher reference 
target for intact parathyroid hormone (iPTH) (2-9 times the 
upper level of the normal range) when compared with the 
National Kidney Foundation (NKF) guidelines published in 
2003 (150-300 pg/mL) (14).
The aim of the Optimal Anemia Treatment in End Stage 
Renal Disease (ESRD) (Optimal ESRD Treatment) study is to 
test whether a tighter PTH control is associated with an ESA 
dose reduction and a slower CV system deterioration in ESRD 
patients receiving dialysis.
Methods
The Optimal ESRD Treatment study is a pilot, pragmatic, 
single-center, open-label trial with a blinded end point (pro-
spective randomized open blinded end-point [PROBE] de-
sign) aimed at improving patient care. The study protocol 
was reviewed and approved by the local ethics committee of 
Azienda Ospedaliera Sant’Anna, Como (Parere Unico 61/13, 
May 16, 2013) and was registered at https://clinicaltrials.gov/ 
(NCT02273570), with the official title “Single-center, Open-la-
bel, Randomized Study of Anemia Management Improvement 
in End Stage Renal Disease (ESRD) Patients With Secondary 
Hyperparathyroidism.” All procedures involved in the study 
will be conducted in adherence to the Declaration of Helsinki 
and the Ethical Principles for Medical Research Involving Hu-
man Subjects, and according to the principles of Good Clinical 
Practice. 
The Optimal ESRD Treatment study objectives are as fol-
lows:
1. Primary objective: to test whether a tighter PTH control 
(PTH level <300 pg/mL vs. PTH level between 300 and 
540 pg/mL) is associated with a lower ESA dose use to 
achieve the target Hb of 10.0-11.5 g/dL.
2. Secondary objective: to test whether a tighter PTH con-
trol to achieve a PTH level <300 pg/mL vs. PTH level be-
tween 300 and 540 pg/mL is associated with a better 
iron storage mobilization.
3. Secondary objective: to test whether a tighter PTH con-
trol to achieve a PTH level <300 pg/mL vs. PTH level 
between 300 and 540 pg/mL is associated with cardiac 
valve deposition and progression attenuation (assessed 
via echocardiogram).
4. Secondary objective: to test whether a tighter PTH con-
trol to achieve a PTH level <300 pg/mL vs. PTH level be-
tween 300 and 540 pg/mL is associated with an increase 
in arterial stiffness attenuation (assessed via applanation 
tonometry).
5. Secondary objective: to test whether a tighter PTH con-
trol to achieve a PTH level <300 pg/mL vs. PTH level be-
tween 300 and 540 pg/mL is associated with a better 
CKD-MBD control.
Eligible patients should be adult men and women (i.e., age 
>18 years), on thrice-weekly maintenance dialysis via arte-
riovenous fistula. They should be undergoing treatment with 
an ESA with an Hb level at study entry between 10.0 and 
11.5 g/dL, iPTH between 300 and 600 pg/mL and Kt/V >1.2. 
Finally, all study participants should able to provide a signed 
informed consent prior to the initiation of the study.
All eligible patients will be randomized (1:1) to one of the 
study arms in which a different PTH control will be enforced 
during the 12 months of study follow-up:
1. Control group (standard care group): the iPTH target in 
this group is 300-540 pg/mL.
2. Optimal CKD-MBD control group: in this group, the PTH 
target is 150-300 pg/mL, to be achieved with a therapeu-
tic algorithm.
To achieve the desired PTH (according to study arm alloca-
tion) and Hb (10.0-11.5 g/dL) levels, no specific therapeutic 
algorithm is to be enforced, and the attending physician will 
be responsible for prescriptions as well as dose titration of 
the different drugs available on the market for CKD-MBD and 
anemia management.
To detect meaningful changes in CV structure and function 
associated with levels of iPTH, the presence of cardiac valve 
calcification, cardiac function and arterial stiffness will be as-
sessed noninvasively via transthoracic echocardiogram and ap-
planation tonometry at study entry as well as study completion 
(Tab. I summarizes the Optimal ESRD Treatment study check-
list). Briefly, a standard transthoracic echocardiogram will be 
performed. Parasternal short and long axes as well as 4- and 
5-chamber views will be acquired to assess cardiac structure 
and function. In particular, the presence and extension of car-
diac valve calcification will be scored as suggested by Corciu 
and collaborators (15). Arterial stiffness and thoracic aorta 
blood pressure will be evaluated noninvasively and expressed 
as pulse wave velocity, thoracic aorta central blood pressure 
and augmentation index. To reduce the intra- and inter-reader 
variability, echocardiogram and applanation tonometry will be 
performed before the midweek dialysis session, and echocar-
diogram readings will be centralized.
It was anticipated that the entire study should take 
about 18 months (from first patient in to last patient out): 
6-month recruitment phase and 12-month active treatment 
period. Active patient recruitment began in March 2015. 
However, as of September 2015, only 17 patients had been 
randomized, due to a slower than anticipated recruitment 
rate, and it is now anticipated that the study will last until 
February 2017.
The Optimal ESRD Treatment study is funded by an un-
restricted research grant from Amgen and from the Italian 
Society of Nephrology.
Statistical analysis and sample size estimation
Standard descriptive statistics as well as parametric and 
nonparametric tests will be used. Linear regression models 
will be adopted to test the difference in ESA use, cardiac valve 
calcification and arterial stiffness between groups at study 
completion. All efficacy analyses will be performed on an 
intention-to-treat basis.
According to the study protocol, the primary end point 
is defined as percentage reduction in weekly ESA consump-
tion to maintain Hb levels within the recommended range 
10.0-11.5 g/dL.
Bellasi et al  e19
© 2016 The Authors. Published by Wichtig International
The following secondary end points will also be inves-
tigated:
• Change in iron status and storage, defined as change in 
iron consumption per week, percentage of patients with 
transferrin saturation >20% between groups at study 
completion, change in hepcidin levels between groups 
at study completion. These end points will be compared 
between and within treatment groups.
• Difference (absolute change and percentage increase) 
in prevalence of valvular calcification deposition and 
progression as detected by echocardiography between 
groups. This end point will be compared between and 
within treatment groups.
• Difference (absolute change and percentage increase) in 
pulse wave velocity as assessed by applanation tonom-
etry between groups. This end point will be compared 
between and within treatment groups.
Given that that this is a pilot study and there are no data for 
an accurate sample size estimation, and assuming: (i) 40% 
ESA dose reduction in the Optimal CKD-MBD control group, 
(ii) power 80%, (iii) statistical significance 5% and (iv) dropout 
rate of 10%, it is estimated that 50 patients (n = 25 per study 
arm) are needed.
Discussion
Observational studies suggest a close association be-
tween CKD-MBD and anemia. Nonetheless, no RCT has in-
vestigated whether CKD-MBD manipulation may ameliorate 
anemia control in ESRD (11-13). The aim of the Optimal 
ESRD Treatment study is to test whether a strict PTH con-
trol (i.e., 150-300 pg/mL vs. 300-540 pg/mL) reduces ESA 
 consumption in a cohort of 50 patients on maintenance di-
alysis. The secondary objectives of the Optimal ESRD Treat-
ment study are to investigate the impact on the CV system, 
of 2 different iPTH targets within the suggested range of 
twofold to ninefold the upper level of the laboratory refer-
ence for iPTH (14).
The Optimal ESRD Treatment study is a pragmatic trial. 
Indeed, with the exception of a vitamin D usage limitation 
(i.e., the cumulative weekly dose of paricalcitol or equivalent 
should not exceed 6 μg), no specific recommendations on 
drug use to achieve the desired levels of iPTH and Hb are to 
be enforced. The attending physician is free to prescribe and 
adjust doses of commonly available drugs for CKD-MBD and 
anemia management.
Although patient recruitment has been slower than ex-
pected and a protocol amendment is under evaluation to 
not limit patient eligibility to individuals with arteriovenous 
fistula as vascular access, it is anticipated that the study will 
be completed and the study results available in spring 2017.
The single-center design and small sample size are indeed 
limitations of this pilot study. Nonetheless, the Optimal ESRD 
Treatment study will shed some light on the feasibility of fu-
ture larger studies in this domain. Far more importantly, it will 
provide some hints for how to optimize ESRD patient care. An 
ongoing, large, properly powered, multicenter study is test-
ing the hypothesis that ESA dose is linked to poor outcome 
in ESRD (16). Knowing what factors are associated with in-
creased use of ESA and knowing that manipulation of bone 
mineral abnormalities may result in ESA use or dose mini-
mization will ultimately result in improved patient care. Al-
though only 50 patients will participate in the study, the fact 
that all study participants receive maintenance dialysis in a 
single center, as well as the centralization of laboratory and 
imaging procedures, should minimize the between-center 
TABLE I - Optimal ESRD Treatment study checklist
Month 1 2 3 4 5 6 7 8 9 10 11 12
Visit no. V1 V2 V3 V4 V5 V6 V7 V8 V9 V10 V11 V12
Patient history X
Concomitant medication X X X X X X X X X X X X
Physical examination X X X X X X X X X X X X
Vital signs X X X X X X X X X X X X
ECG X X
Biobank X X
Lab tests* X X X X X X X X X X X X
Cardiac valve calcification assessment X X
Arterial stiffness assessment X X
iPTH target X X X X X X X X
Safety assessment X X X X X X X X X X X X
ECG = echocardiography; iPTH = intact parathyroid hormone.
* As per standard practice.
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and inter-reader variability, thus increasing the chance to de-
tect a meaningful result if it exists.
In summary, the Optimal ESRD Treatment study aims to 
shed light on any causative association between PTH and 
anemia. The study results are expected for spring 2017, and it 
is the authors’ opinion that they will be valuable for improved 
patient care and/or for future larger studies to be undertaken 
in this domain.
Disclosures
Financial support: The Optimal ESRD Treatment study is funded by 
an unrestricted research grant from Amgen and from the Italian So-
ciety of Nephrology.
Conflict of interest: None of the authors has any financial interest 
related to this study to disclose.
References
1. National Kidney Foundation. KDOQI clinical practice guidelines 
and clinical practice recommendations for anemia in chronic 
kidney disease: 2007 update of hemoglobin target. Am J Kid-
ney Dis. 2007;50:471-530.
2. National Kidney Foundation. K/DOQI clinical practice guide-
lines for bone metabolism and disease in chronic kidney dis-
ease. Am J Kidney Dis. 2003;42:S1-S201.
3. Locatelli F, Nissenson AR, Barrett BJ, et al. Clinical practice 
guidelines for anemia in chronic kidney disease: problems and 
solutions. A position statement from Kidney Disease: Improv-
ing Global Outcomes (KDIGO). Kidney Int. 2008;74:1237-1240.
4. Locatelli F, Pisoni RL, Akizawa T, et al. Anemia management for 
hemodialysis patients: Kidney Disease Outcomes Quality Initia-
tive (K/DOQI) guidelines and Dialysis Outcomes and Practice 
Patterns Study (DOPPS) findings. Am J Kidney Dis. 2004;44: 
27-33.
5. Pisoni RL, Bragg-Gresham JL, Young EW, et al. Anemia man-
agement and outcomes from 12 countries in the Dialysis Out-
comes and Practice Patterns Study (DOPPS). Am J Kidney Dis. 
2004;44:94-111.
6. Regidor DL, Kopple JD, Kovesdy CP, et al. Associations between 
changes in hemoglobin and administered erythropoiesis-stim-
ulating agent and survival in hemodialysis patients. J Am Soc 
Nephrol. 2006;17:1181-1191.
7. Lacson E Jr, Ofsthun N, Lazarus JM. Effect of variability in ane-
mia management on hemoglobin outcomes in ESRD. Am J Kid-
ney Dis. 2003;41:111-124.
8. Gilbertson DT, Ebben JP, Foley RN, Weinhandl ED, Bradbury BD, 
Collins AJ. Hemoglobin level variability: associations with mor-
tality. Clin J Am Soc Nephrol. 2008;3:133-138.
9. Fishbane S, Berns JS. Hemoglobin cycling in hemodialysis pa-
tients treated with recombinant human erythropoietin. Kidney 
Int. 2005;68:1337-1343.
10. Ebben JP, Gilbertson DT, Foley RN, Collins AJ. Hemoglobin 
level variability: associations with comorbidity, intercurrent 
events, and hospitalizations. Clin J Am Soc Nephrol. 2006; 
1:1205-1210.
11. Fusaro M, D'Angelo A, Naso A, et al. Treatment with calcimi-
metic (cinacalcet) alters epoetin dosage requirements in dialy-
sis patients: preliminary report. Ren Fail. 2011;33:732-735.
12. Battistella M, Richardson RM, Bargman JM, Chan CT. Improved 
parathyroid hormone control by cinacalcet is associated with 
reduction in darbepoetin requirement in patients with end-
stage renal disease. Clin Nephrol. 2011;76:99-103.
13. Capuano A, Serio V, Pota A, Memoli B, Andreucci VE. Benefi-
cial effects of better control of secondary hyperparathyroidism 
with paricalcitol in chronic dialysis patients. J Nephrol. 2009; 
22:59-68.
14. Kidney Disease Improving Global Outcomes (KDIGO) CKD-
MBD Work Group. KDIGO clinical practice guideline for the 
diagnosis, evaluation, prevention, and treatment of chronic 
kidney disease-mineral and bone disorder (CKD-MBD). Kid-
ney Int Suppl. 2009;76:S1-S130. 
15. Corciu A, Siciliano V, Poggianti E, Petersen C, Venneri L, 
Picano E. Cardiac calcification by transthoracic echocardiog-
raphy in patients with known or suspected coronary artery 
disease. Int J Cardiol. 2010;23;142(3):288-295.
16. Strippoli GF; Clinical Evaluation of the Dose of Erythropoietins 
Study Group (C.E. DOSE). Effects of the dose of erythropoiesis 
stimulating agents on cardiovascular events, quality of life, and 
health-related costs in hemodialysis patients: the Clinical Eval-
uation of the Dose of Erythropoietins (C.E. DOSE) trial protocol. 
Trials. 2010;11:70.
